Back to announcement
KLBF - Penjelasan Perubahan Liabilitas_final.pdf
Financial statement Text extracted KLBFSource file signed link, expires in 15 minutes
Extracted text 2
Page 1
No. : 016/CSEC-KF/III-2026 Jakarta, 30 Maret 2026 Lampiran : - Kepada Yth./To Otoritas Jasa Keuangan Gedung Sumitro Djojohadikusumo Jl. Lapangan Banteng Timur 2-4 Jakarta 10710 Indonesia U.p.: Kepala Eksekutif Pengawas Pasar Modal Direksi PT Bursa Efek Indonesia Indonesia Stock Exchange Building, Tower I Jl. Jend. SudirmanKav. 52-53 Jakarta 12190 Indonesia U.p.: Direktur Pencatatan Perihal : Penjelasan PT Kalbe Farma Tbk dan Subject: Explanation by PT Kalbe Farma Tbk Entitas Anak (“Perseroan) tentang and Its Subsidiaries (“the Company”) Perubahan Lebih dari 20% (Dua Puluh Regarding the Change of More Than 20% Persen) pada Total Liabilitas (Twenty Percent) in Total Liabilities Dengan hormat, With respect, Merujuk pada Peraturan Bursa Efek Indonesia Referring to Indonesia Stock Exchange Nomor I-E tentang Kewajiban Penyampaian Regulation Number I-E on the Obligation to Informasi, butir III.1.1.4. dimana apabila terdapat Submit Information, item III.1.1.4, whereby in the perubahan lebih dari 20% (dua puluh persen) event of a change exceeding 20% (twenty pada Jumlah Aset dan/atau Jumlah Liabilitas percent) in the Total Assets and/or Total pada Laporan Keuangan Interim atau Laporan Liabilities in the Interim Financial Statements or Keuangan Tahunan periode tahun buku the Annual Financial Statements for the current berjalan dibandingkan dengan Laporan financial year compared with the most recent Keuangan Tahunan Auditan terakhir maka Audited Annual Financial Statements, the Listed bersamaan dengan penyampaikan Laporan Company is required, concurrently with the Keuangan Perusahaan Tercatat wajib submission of its Financial Statements, to memberikan penjelasan tertulis kepada Bursa provide the Exchange with a written explanation tentang penyebab perubahan berikut regarding the causes of such change and pendapat manajemen tentang dampak management’s opinion on its impact on the perubahan tersebut terhadap kinerja Listed Company’s financial performance during keuangan Perusahaan Tercatat pada tahun the current year. berjalan. Berdasarkan Laporan Keuangan Audit Based on the Consolidated Audited Financial Konsolidasian tanggal 31 Desember 2025 dan Statements as of 31 December 2025 and for the untuk tahun yang berakhir di tanggal tersebut, year then ended, total liabilities as of 31 total liabilitas per 31 Desember 2025 adalah December 2025 amounted to Rp5,970,845 sebesar Rp5.970.845 juta, mengalami million, representing an increase of Rp1,131,551 kenaikan sebesar Rp1.131.551 juta atau setara million or 23.4% compared to the prior year. The PT. KALBE FARMA Tbk. Head Office : Gedung KALBE, Jl. Let. Jend. Suprapto Kav. 4, Jakarta 10510, P.O. Box 3105 JAK, Jakarta, Indonesia. Tel. (021) 42873888 - 89 Fax. (021) 42873680 Factory : Kawasan Industri Delta Silicon, Jl. M. H. Thamrin Blok A3 – 1, Lippo Cikarang, Bekasi 17550, P.O. Box 371 Bekasi 17037. Indonesia. Tel. (021) 89907333 Fax. (021) 8972874 Info@kalbe.co.id
Page 2
dengan 23,4% jika dibandingkan dengan tahun increase in total liabilities was primarily sebelumnya. Kenaikan total liabilitas paling attributable to higher other payables and trade besar disebabkan oleh kenaikan utang lain-lain payables. The increase in other payables mainly serta utang usaha. Kenaikan utang lain-lain arose from the payable related to the transfer of terutama berasal dari utang atas pengalihan shares in the subsidiary, PT Kalbe Genexine saham entitas anak PT Kalbe Genexine Biologics, from General Atlantic to the Company, Biologics milik General Atlantic kepada while the increase in trade payables mainly arose Peseroan sedangkan kenaikan utang usaha from the purchase of raw materials and finished terutama berasal dari pembelian bahan baku goods which was consistent with the Company’s dan barang jadi seiring dengan perkembangan business development. bisnis Perseroan. Manajemen Perseroan berpendapat bahwa In Management’s view, the aforementioned perubahan tersebut sejalan dengan strategi changes are in line with the Company’s business bisnis Perseroan serta tidak berdampak pada strategy and do not adversely impact the penurunan kinerja Perseroan. Perseroan Company’s performance. The Company mampu menjaga rasio utang melalui continues to maintain debt ratios through pengelolaan likuiditas yang baik. prudent liquidity management. Demikian kami sampaikan dan atas We hereby submit this information and thank perhatiannya kami ucapkan terima kasih. you for your kind attention. Hormat kami/ Your sincerely PT Kalbe Farma Tbk Maria Teresa Fabiola Corporate Secretary PT. KALBE FARMA Tbk. Head Office : Gedung KALBE, Jl. Let. Jend. Suprapto Kav. 4, Jakarta 10510, P.O. Box 3105 JAK, Jakarta, Indonesia. Tel. (021) 42873888 - 89 Fax. (021) 42873680 Factory : Kawasan Industri Delta Silicon, Jl. M. H. Thamrin Blok A3 – 1, Lippo Cikarang, Bekasi 17550, P.O. Box 371 Bekasi 17037. Indonesia. Tel. (021) 89907333 Fax. (021) 8972874 Info@kalbe.co.id
Names mentioned 10 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Bursa Efek Indonesia Indonesia Stock Exchange Building
p.1
unresolved
org
Indonesia Stock Exchange
p.1 ×2
unresolved
person
H. Thamrin
p.1 ×2
unresolved
org
PT Kalbe Genexine
p.2 ×2
unresolved
person
Maria Teresa Fabiola
· Corporate Secretary
p.2
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.